-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The new coronavirus (SARS-CoV-2) causes 3-10% of infected people to develop moderate to severe disease
Anne Krug, professor of immunology at the University of Munich’s Biomedical Center, led a team to conduct a comprehensive study of this phenomenon
Dendritic cells (DC) are responsible for initiating an immune response to combat invasive pathogens
They analyzed the blood samples of 65 COVID-19 patients treated at the Munich University Medical Center
"We had predicted that dendritic cells isolated from patients infected with SARS-CoV-2 would activate T cells more effectively than dendritic cells from healthy donors," Krug said
Nevertheless, after 15 days of diagnosis, 90% of patients developed antibodies against the SARS-CoV-2 spike protein, and many of them also activated T cell responses
Despite this, she still believes that the reduction in the number of dendritic cells and the changes in their functions are significant
So, what causes the reduction of dendritic cells in the blood? Krug made several hypotheses
Researchers believe that this phenomenon may weaken the ability of patients to produce effective immune responses to other pathogens during and after COVID-19 infection
###
Winheim E, Rinke L, Lutz K, Reischer A, Leutbecher A, Wolfram L, et al.
